NVO · Novo Nordisk A/S

This 6-K discloses material progress under Novo Nordisk’s DKK 15 billion share repurchase programme, with DKK 3.15 billion executed in just over two months — representing 21% of the total authorization and implying an accelerated pace relative to prior programmes. The average purchase price of DKK 256.87 reflects continued premium valuation, consistent with strong commercial performance of GLP-1 therapies. With 28.4 million B shares now held in treasury (0.6% of total shares), the company has enhanced its capacity for EPS accretion and strategic flexibility, including future employee incentive grants or opportunistic capital deployment. The use of EU Safe Harbour rules ensures regulatory compliance and mitigates market impact concerns, reinforcing governance credibility. While no earnings or guidance is disclosed here, the scale and speed of buybacks signal management’s view that current share price does not fully reflect underlying cash flow generation and growth trajectory — a key sentiment indicator for income- and yield-sensitive investors. The absence of dividend changes or other capital actions underscores buybacks as the primary near-term return mechanism.